ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of $(0.72) by 25.52 percent. This is a 38.46 percent decrease over losses of $(0.65) per share from the same period last year.